Faculty Opinions recommendation of Proteomic analysis of active multiple sclerosis lesions reveals therapeutic targets.

2008 ◽  
Author(s):  
Valder Arruda
Keyword(s):  
Multiple Sclerosis ◽  
Proteomic Analysis ◽  
Therapeutic Targets ◽  
Active Multiple Sclerosis

Proteomic analysis of active multiple sclerosis lesions reveals therapeutic targets

Nature ◽  
2008 ◽  
Vol 451 (7182) ◽  
pp. 1076-1081 ◽  
Author(s):  
May H. Han ◽  
Sun-Il Hwang ◽  
Dolly B. Roy ◽  
Deborah H. Lundgren ◽  
Jordan V. Price ◽  
...  
Keyword(s):  
Multiple Sclerosis ◽  
Proteomic Analysis ◽  
Therapeutic Targets ◽  
Active Multiple Sclerosis

First-line treatment with alemtuzumab for active multiple sclerosis: A nationwide post-marketing survey in Austria

2017 ◽  
Vol 381 ◽  
pp. 796
Author(s):  
F. Otto ◽  
B. Bajer-Kornek ◽  
P. Rommer ◽  
F. Leutmezer ◽  
C. Franta-Elmer ◽  
...  
Keyword(s):  
Multiple Sclerosis ◽  
Line Treatment ◽  
First Line ◽  
Post Marketing ◽  
First Line Treatment ◽  
Active Multiple Sclerosis

Chemokine CCL2 and chemokine receptor CCR2 in early active multiple sclerosis

2004 ◽  
Vol 11 (7) ◽  
pp. 445-449 ◽  
Author(s):  
T. L. Sorensen ◽  
R. M. Ransohoff ◽  
R. M. Strieter ◽  
F. Sellebjerg
Keyword(s):  
Multiple Sclerosis ◽  
Chemokine Receptor ◽  
Active Multiple Sclerosis ◽  
Chemokine Receptor Ccr2

scholarly journals The meninges: new therapeutic targets for multiple sclerosis

2015 ◽  
Vol 165 (2) ◽  
pp. 255-269 ◽  
Author(s):  
Abigail E. Russi ◽  
Melissa A. Brown
Keyword(s):  
Multiple Sclerosis ◽  
Therapeutic Targets ◽  
New Therapeutic Targets

scholarly journals Natalizumab concentrations during pregnancy in three patients with multiple sclerosis

2021 ◽  
pp. 135245852110521
Author(s):  
Alyssa A Toorop ◽  
Theo Rispens ◽  
Eva MM Strijbis ◽  
Bob W van Oosten ◽  
Brigit A de Jong ◽  
...  
Keyword(s):  
Multiple Sclerosis ◽  
Disease Activity ◽  
Third Trimester ◽  
Blood Samples ◽  
The Third ◽  
Trough Concentrations ◽  
Active Multiple Sclerosis

In women with very active multiple sclerosis (MS), natalizumab can be continued during pregnancy to prevent rebound disease activity. Our aim was to evaluate changes in serum natalizumab trough concentrations during pregnancy. Blood samples of 3 patients were collected before, during, and after pregnancy. Natalizumab trough concentrations gradually decreased during pregnancy. The patient with the lowest trough concentrations during the third trimester was treated with extended interval dosing (EID). After delivery, natalizumab concentrations increased to similar levels as before pregnancy. All patients remained clinically and radiologically stable. MS neurologists should be aware of decreasing natalizumab concentrations during pregnancy, especially in patients with low initial trough concentrations and patients with EID.

Low expression of interferon-stimulated genes in active multiple sclerosis is linked to subnormal phosphorylation of STAT1

2002 ◽  
Vol 129 (1-2) ◽  
pp. 205-215 ◽  
Author(s):  
Xuan Feng ◽  
Anthony L Petraglia ◽  
Michael Chen ◽  
Paul V Byskosh ◽  
Markus D Boos ◽  
...  
Keyword(s):  
Multiple Sclerosis ◽  
Interferon Stimulated Genes ◽  
Low Expression ◽  
Active Multiple Sclerosis
Sign in / Sign up

Export Citation Format

Share Document